| Literature DB >> 34354245 |
Mehul Patel1, Akhil Muthigi2, Ranjith Ramasamy3.
Abstract
Testosterone therapy (TT) for the treatment of testosterone deficiency (TD) can be administered via several routes of administration. Due to a variety of concerns such as hepatotoxicity, an oral formulation has long been absent in the United States. Recently, JATENZO® (testosterone undecanoate) oral capsules was approved by the US FDA as an oral option for men suffering from TD. In this article, we will discuss the history and challenges in the development of a viable oral formulation of exogeneous TT and examine how JATENZO® addresses these concerns.Entities:
Year: 2021 PMID: 34354245 DOI: 10.1038/s41443-021-00461-4
Source DB: PubMed Journal: Int J Impot Res ISSN: 0955-9930 Impact factor: 2.896